Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Infectious Disease·MeSH: Fatty Liver
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| tvb-2640 | Sagimet Biosciences Inc. (SGMT) |
Frequently asked questions
How many drugs are in development for Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease?
BioSniper tracks 1 drug in development for Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease across 1 company.
How many clinical trials target Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease?
There are 1 clinical trial targeting Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease tracked by BioSniper.
Deep-dive into Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis